- Home
- KPRX vs TENX Comparison
KPRX vs TENX Comparison
Compare KPRX & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- TENX
- Stock Information
- Founded
- KPRX 1998
- TENX 1967
- Country
- KPRX United States
- TENX United States
- Employees
- KPRX N/A
- TENX N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- KPRX Health Care
- TENX Health Care
- Exchange
- KPRX Nasdaq
- TENX Nasdaq
- Market Cap
- KPRX 11.0M
- TENX 11.4M
- IPO Year
- KPRX N/A
- TENX N/A
- Fundamental
- Price
- KPRX $3.18
- TENX $4.99
- Analyst Decision
- KPRX Strong Buy
- TENX Strong Buy
- Analyst Count
- KPRX 1
- TENX 4
- Target Price
- KPRX $10.00
- TENX $20.67
- AVG Volume (30 Days)
- KPRX 45.3K
- TENX 96.4K
- Earning Date
- KPRX 11-19-2024
- TENX 11-13-2024
- Dividend Yield
- KPRX N/A
- TENX N/A
- EPS Growth
- KPRX N/A
- TENX N/A
- EPS
- KPRX 1.53
- TENX N/A
- Revenue
- KPRX $16,020,000.00
- TENX N/A
- Revenue This Year
- KPRX N/A
- TENX N/A
- Revenue Next Year
- KPRX N/A
- TENX N/A
- P/E Ratio
- KPRX $2.29
- TENX N/A
- Revenue Growth
- KPRX N/A
- TENX N/A
- 52 Week Low
- KPRX $3.00
- TENX $2.77
- 52 Week High
- KPRX $8.98
- TENX $41.92
- Technical
- Relative Strength Index (RSI)
- KPRX 43.73
- TENX 64.74
- Support Level
- KPRX $3.47
- TENX $4.50
- Resistance Level
- KPRX $3.75
- TENX $5.09
- Average True Range (ATR)
- KPRX 0.22
- TENX 0.27
- MACD
- KPRX -0.03
- TENX 0.01
- Stochastic Oscillator
- KPRX 0.00
- TENX 81.01
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.